WHO Sounds Alert Over Critical Lack of Weight-Loss Jabs

Less than a tenth of people who could benefit from GLP-1 drugs like Wegovy have access to them, states the WHO as it publishes its inaugural advice on the medications.

Considering more than one billion individuals worldwide now living with obesity, it is advocating for increased and just access to these injectable treatments.

Per forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.

"The latest guidance recognises that obesity is a lifelong illness that can be managed with thorough and lifelong care," said the agency's head Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and logistical bottlenecks are major obstacles to universal access to the jabs that can assist patients in reducing significant body mass, says the body.

GLP-1 Therapy Supply Crisis

Despite the current best projected scenario, the production of such drugs could only cover around 100 million people – under 10% of those who need them, per the health organization.

The advice calls on governments and firms to expand availability, by measures like voluntary licensing.

Exclusive production rights on semaglutide – the primary component of the drug Wegovy – is scheduled to end in a number of countries in 2026.

The Way Obesity Drugs Work

GLP-1 drugs mimick a biological compound to delay gastric emptying, reduce hunger and enhance the sense of being full so people reduce food intake.

People commonly start to lose weight in the initial weeks of commencing the once-weekly jabs.

Evidence points to users may regain a significant portion a year later of halting the drug, because their typical hunger resume.

To be overweight or obese raises your risk for experiencing health problems, like type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.

Excess weight impacts people in all nations and was linked to 3.7 million deaths worldwide in 2024, according to the health agency.